Cargando…
Myocarditis-myositis-myasthenia gravis overlap syndrome depending on immune checkpoint inhibitor
Immune checkpoint inhibitors are breakthrough monoclonal antibodies in cancer therapy developed against mechanisms that suppress the immune response. After the devastating effects of chemotherapy, these specific agents have given hope to cancer patients. However, every drug has side effects itself a...
Autores principales: | Ünlütürk, Zeynep, Karagülmez, Ahmet Mağrur, Hayti, Barış, Erdoğan, Çağdaş |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific Scholar
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9945139/ https://www.ncbi.nlm.nih.gov/pubmed/36891103 http://dx.doi.org/10.25259/JNRP_10_2022 |
Ejemplares similares
-
Immune checkpoint inhibitor induced myocarditis, myasthenia gravis, and myositis: A single‐center case series
por: Longinow, Joshua, et al.
Publicado: (2022) -
Case Report: The Neuromusclar Triad of Immune Checkpoint Inhibitors: A Case Report of Myositis, Myocarditis, and Myasthenia Gravis Overlap Following Toripalimab Treatment
por: Luo, Yue-Bei, et al.
Publicado: (2021) -
Myocarditis and myositis/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature
por: Yin, Beibei, et al.
Publicado: (2022) -
Nivolumab-Induced Myasthenia Gravis Concomitant With Myocarditis, Myositis, and Hepatitis
por: Bawek, Sawyer J, et al.
Publicado: (2021) -
Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report
por: Cham, Jason, et al.
Publicado: (2021)